common.study.topics.clinical

Insulin Regulation of Lipolysis and Lipolysis Proteins

common.study.values.description

Insulin Regulation of Lipolysis and Lipolysis Proteins

These studies will define the abnormalities in the adipocyte proteins that are involved in the failure of insulin to suppress lipolysis normally in humans with upper body obesity and will help discover the mechanism by which pioglitazone, a medication used to treat type 2 diabetes and improve insulin resistance, improves insulin-regulation of adipocyte fatty acid metabolism.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Behavioral - Immediate weight loss

Upper body obese subjects will undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.

Drug - Pioglitazone

Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.

Behavioral - Deferred weight loss

Upper body obese subjects will complete a weight-stable period of 4 months and subsequently undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.

Drug - Placebo

Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.

participant.views.study.view.additional

participant.views.study.view.scientific-title

Insulin Regulation of Lipolysis and Lipolysis Proteins

common.study.values.clinical-trial-id

NCT03866408

participant.views.study.view.id

bqxoDa